As we start 2012, the economic outlook for the year remains
clouded across the globe. European woes continue to dominate the
headlines while concerns over a slowdown in China and the U.S. are
likely to weigh on the markets unless more positive data hits the
wires. Beyond these issues, politics are also looking to play a key
role in 2012 as elections in the U.S. and Russia, as well as
tensions with Iran, could spook the markets at any time.
Despite these worries, some are cautiously optimistic about the
New Year and the market going forward. These predictions could be
accurate if inflation remains under control in emerging markets,
there aren’t any geopolitical flare ups, and if the U.S. economy
can continue to grow at its modest pace, helping to buoy the global
economy. In fact, the ISM in the U.S. has risen to a six-month high
in the most recent reading, suggesting that European concerns are
still not really being felt by many U.S. businesses and that we
could skirt a double dip recession (see Three Outperforming Active
ETFs).
In light of the uncertainty, more ‘tactical’ as opposed to
‘broad based’ picks may be the way to go in this environment as
they could help investors to be more nimble in this rocky year.
Furthermore, these tactical choices could be better targeted at the
true growth corners of the economy or sections that may have lower
levels of risk in this volatile atmosphere. With this in mind, we
have selected five surgical allocations that investors may want to
make in 2012 over their more broad based counterparts, especially
if the status quo in the market continues throughout the year:
MSCI Malaysia Index Fund (EWM) over MSCI Emerging Markets ETF (VWO)
With broad emerging markets facing a host of issues to start the
year, many investors are worried about putting large amounts of
capital to work in these surging nations. This could be especially
true if the Chinese real estate bubble bursts, tensions heat up in
Korea, or a slump in commodity prices hurts Brazil. All three of
these issues could heavily impact VWO in 2012 as the fund allocates
close to 50% of its assets to these three countries suggesting that
it could be particularly impacted by these concerns (see Top Three
BRIC ETFs)..
Instead, investors may be better off considering a smaller
nation such as Malaysia and its main ETF EWM which continues to fly
under the radar. In addition to being a major export market for a
variety of goods both basic and high tech, the country is a major
center for Islamic banking as well. This sector could continue to
grow and help the Malaysian economy as oil rich Arab states push
more capital into the nation as a safe way to diversify portfolios
into another Islamic nation. EWM has close to 30% of its assets in
financials, and the next three biggest sectors are industrials,
consumer staples and consumer discretionary, suggesting that the
fund is pretty well diversified and could be a solid pick no matter
what happens this year in the other emerging Asian markets.
S&P Oil & Gas Exploration & Production Fund (XOP) over
Energy Select Sector SPDR (XLE)
The energy market certainly picked up steam in the final few
months of the year helping to push XLE to a gain of 3.1% in 2011 on
a 25.4% surge in the fourth quarter. This run could continue in
2012 especially if there is more turmoil in the Arab world or if
tensions with Iran continue to remain high. Unfortunately, many
large Western oil companies are frozen out of emerging markets
thanks to the rise of state owned or state backed oil firms such as
Petrobras, Petronas and Sinopec. Thanks to this, extra supplies in
growing markets could be hard to come by for ‘big oil’ this year
(read Time To Consider The Small Cap Oil ETF).
As a result, many investors may want to consider looking at
firms that are engaged in exploration activities instead as these
firms could play a very crucial role for firms looking to boost
production in the face of high crude prices. In fact, this has
already been the case over the past few months as XOP has
outperformed XLE in the fourth quarter, gaining 35.7% in the
period. Should oil prices remain high this segment could continue
to outperform this year and be a solid pick for investors seeking
more exposure to crude oil in equity form.
Intermediate Corporate Bond Index Fund (VCIT) over Extended
Duration Treasury Index ETF (EDV)
Long-term bonds had an incredible run over the course of 2011 as
one of the longest duration ETFs, EDV, gained nearly 45.6% on the
year with virtually all of the gains coming between August and
September. Yet after that period, EDV slumped heavily as the fund
lost about 7.8% over the last three months of the year as investors
sought higher yielding bonds or equities. Given that Treasury bonds
are still approaching all-time lows and that a 30 year bond only
offers a 3% yield, one has to believe that this trend out of
Treasury bonds could continue this year as well (also read Do You
Need A Floating Rate Bond ETF?).
If one believes this to be the case, a closer look at VCIT could
be warranted. Not only does the fund pay out a higher yield than
its Treasury counterpart—3.8% to 3.0%-- but the fund has a far
lower level of duration risk. In fact, the average duration is just
6.2 years for VCIT while it is close to four times that figure for
EDV. This suggests that if interest rates trend higher, VCIT will
be far less impacted than its long-dated counterpart from a
negative perspective. This means that while the fund has
underperformed EDV in 2011, if interest rates trend modestly higher
towards historical levels, we could see VCIT be the winner instead
this year.
S&P Biotech Fund (XBI) over Health Care Select Sector SPDR
(XLV)
Health care was another big winner in 2011 as investors trended
into the safe haven as protection from further market turmoil. XLV
gained close to 10.5% on the year thanks to these worries,
including a 14.4% jump in the past quarter alone. Yet, despite
these gains, there are some concerns over the industry this year.
First, the political uncertainty in the U.S. could rock the broad
health care market, especially if any large changes to ‘ObamaCare’
look likely to be pushed through Congress. Additionally, many large
pharma firms are quickly running out of profitable drugs and their
pipelines remain anemic to say the least, suggesting that it could
be a rough period if there aren’t a few big discoveries in the near
term (also read Three Low Beta Sector ETFs).
In order to avoid most of these worries, a closer look at the
biotech sector may be the way to go for those seeking more exposure
to the health care market. Biotech firms generally have better
pipelines than their pharma counterparts and have better growth
prospects as well. Additionally, as big pharma gets more desperate,
a push to acquire biotech firms could be made by those flush with
cash in an attempt to bolster growth prospects. Thanks to these
reasons, as well as the uncertainty plaguing much of the rest of
the health care space, biotech could be a star performer in the
space for 2012.
China AlphaDEX Fund (FCA) over FTSE China 25 Index Fund (FXI)
Concerns over China and a slowdown in the country could be among
the most important stories in the market this year. Housing is
unaffordable for many and there are some concerns over the ability
of the country to transition to a more consumer and internally
focused nation as opposed to its current role as an export
powerhouse. Thanks to these worries, speculation is beginning to
build over massive losses at banks across the country, especially
if the property bubble bursts in the country at some point this
year. This could be especially bad news for China ETFs such
as FXI as the fund has close to 50% of its portfolio in financials
and is thus heavily exposed to any broad banking crisis in the
country (read Forget FXI Try These China ETFs Instead).
Instead, a look at a slightly more ‘active’ fund could be the
way to go for those seeking more China exposure in this uncertain
time. FCA has a much more modest allocation to financials of just
under 20% of the total assets and it uses a more methodical
approach to select holdings. Instead of just allocation based on
market cap as many funds do, FCA ranks eligible stocks by growth
and value factors, picking the best 50 for inclusion in the fund.
Thanks to this more qualitative approach and the smaller level of
exposure to financials, we look for the fund to outperform FXI in
2012, although it is very possible for both to see severe weakness
once again on the year.
Want the latest recommendations from Zacks Investment Research?
Today, you can download 7 Best Stocks for the Next 30
Days. Click to get this free report >>
Long EWM and VWO.
To read this article on Zacks.com click here.
Zacks Investment Research
Want the latest recommendations from Zacks Investment Research?
Today, you can download 7 Best Stocks for the Next 30 Days. Click
to get this free report
Grafico Azioni SPDR S&P Biotech (AMEX:XBI)
Storico
Da Nov 2024 a Dic 2024
Grafico Azioni SPDR S&P Biotech (AMEX:XBI)
Storico
Da Dic 2023 a Dic 2024